基于深度学习的CUETO和EORTC预测工具再校准用于非肌层浸润性膀胱癌复发和进展
本研究利用深度神经网络(DeepSurv)对CUETO和EORTC风险分层工具进行再校准,训练组3570例初诊非肌层浸润性膀胱癌患者,外部验证组322例。模型在验证组中预测无复发生存(RFS)的C指数为0.651(95%CI 0.648-0.654),预测无进展生存(PFS)的C指数为0.881(95%CI 0.878-0.885),表现优于标准工具且无过拟合证据。应用已开源。
要点
- 深度学习模型在外部验证中RFS的C指数为0.651,PFS为0.881。
- 模型优于EORTC/CUETO标准风险分层工具,且无过拟合证据。
- 开源工具已在线提供,可用于预测NMIBC复发和进展。
核心结论
- 深度学习再校准模型在预测NMIBC的RFS和PFS上优于标准风险分层工具,且外部验证无过拟合证据。
研究设计与样本
- 回顾性联合队列数据挖掘研究,训练组3570例初诊NMIBC患者,外部验证组322例。
- 使用Cox比例风险深度神经网络(DeepSurv)建模,并进行超参数网格搜索。
主要发现
- 在手术和卡介苗治疗患者中,训练组RFS的C指数为0.650(95%CI 0.649-0.650),PFS为0.878(95%CI 0.873-0.874)。
- 验证组RFS的C指数为0.651(95%CI 0.648-0.654),PFS为0.881(95%CI 0.878-0.885)。
- 纳入丝裂霉素C治疗患者后,训练组RFS的C指数为0.6415(95%CI 0.6412-0.6417),验证组为0.660(95%CI 0.657-0.664)。
- PFS模型训练组C指数为0.885(95%CI 0.885-0.885),验证组为0.876(95%CI 0.873-0.880)。
临床怎么用
- 该开源工具可用于NMIBC患者复发和进展的个体化预测,辅助临床决策。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 外部验证队列样本量较小(322例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite being standard tools for decision-making, the European Organisation for Research and Treatment of Cancer (EORTC), European Association of Urology (EAU), and Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk groups provide moderate performance in predicting recurrence-free survival (RFS) and progression-free survival (PFS) in non-muscle-invasive bladder cancer (NMIBC). In this retrospective combined-cohort data-mining study, the training group consisted of 3570 patients with de novo diagnosed NMIBC. Predictors included gender, age, T stage, histopathological grading, tumor burden and diameter, EORTC and CUETO scores, and type of intravesical treatment. The models developed were externally validated using an independent cohort of 322 patients. Models were trained using Cox proportional-hazards deep neural networks (deep learning; DeepSurv) with a proprietary grid search of hyperparameters. For patients treated with surgery and bacillus Calmette-Guérin-treated patients, the models achieved a c index of 0.650 (95% confidence interval [CI] 0.649-0.650) for RFS and 0.878 (95% CI 0.873-0.874) for PFS in the training group. In the validation group, the c index was 0.651 (95% CI 0.648-0.654) for RFS and 0.881 (95% CI 0.878-0.885) for PFS. After inclusion of patients treated with mitomycin C, the c index for RFS models was 0.6415 (95% CI 0.6412-0.6417) for the training group and 0.660 (95% CI 0.657-0.664) for the validation group. Models for PFS achieved a c index of 0.885 (95% CI 0.885-0.885) for the training set and 0.876 (95% CI 0.873-0.880) for the validation set. Our tool outperformed standard-of-care risk stratification tools and showed no evidence of overfitting. The application is open source and available at https://biostat.umed.pl/deepNMIBC/. PATIENT SUMMARY: We created and validated a new tool to predict recurrence and progression of early-stage bladder cancer. The application uses advanced artificial intelligence to combine state-of-the-art scales, outperforms these scales for prediction, and is freely available online.
引用
- Jobczyk M, Stawiski K, Kaszkowiak M, et al. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2021. PMID: 34092528. doi:10.1016/j.euo.2021.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。